Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | PIP4K2A | P48426 | 7/20 | 0.43 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | TNF | P01375 | 2/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | PIP4K2B | P78356 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3801046 | 0.91 | EGFR (0.46) | KMT2AMEN1PIP4K2APIP4K2CEGFR | |
| SCHEMBL3798859 | 0.89 | PIP4K2A (0.44) | KMT2AMEN1PIP4K2APIP4K2CEGFR | |
| SCHEMBL3798518 | 0.89 | PIP4K2A (0.44) | KMT2AMEN1PIP4K2APIP4K2CEGFR | |
| SCHEMBL3798525 | 0.88 | KMT2A (0.43) | KMT2AMEN1PIP4K2APIP4K2CEGFR | |
| SCHEMBL3797069 | 0.84 | PIP4K2C (0.42) | PIP4K2CEGFRRAB9AHTTSMN1; SMN2 | |
| SCHEMBL3802210 | 0.83 | MEN1 (0.44) | KMT2AMEN1EGFRRAB9ATNF | |
| SCHEMBL3800042 | 0.82 | EGFR (0.47) | KMT2AMEN1EGFRRAB9ATNF | |
| SCHEMBL3799620 | 0.82 | MEN1 (0.44) | KMT2AMEN1EGFRALKRAB9A | |
| SCHEMBL3795832 | 0.80 | MEN1 (0.43) | KMT2AMEN1EGFRRAB9ANPC1 | |
| SCHEMBL3797986 | 0.79 | MEN1 (0.54) | KMT2AMEN1PIP4K2AEGFRRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100143341-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2010-06-10 | — | — | US | claimed |
| EP-1899353-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DeveloGen Aktiengesellschaft (DE) | 2008-03-19 | — | — | EP | claimed |
| WO-2006136402-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2006-12-28 | — | — | WO | claimed |
| US-20100247517-A1 | USE OF MNK INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Boehringer Ingelheim Internationational GmbH (DE) | 2010-09-30 | — | — | US | disclosed |
| US-20100143341-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2010-06-10 | — | — | US | disclosed |
| EP-1899353-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DeveloGen Aktiengesellschaft (DE) | 2008-03-19 | — | — | EP | disclosed |
| WO-2006136402-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100247517-A1 | USE OF MNK INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | NEK9, TTBK1, NEK2 | KMT2A 1015/4885MEN1 1746/4885PIP4K2A 453/4885 |
| US-20100143341-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DTYMK, CMPK1, PDXK | KMT2A 1016/4885MEN1 1106/4885PIP4K2A 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.